Eli Lilly stock recently achieved a significant milestone, reaching a 52-week high of $935.68, with shares now trading at $935.97. This marks a notable achievement for the pharmaceutical giant, ...

In a bid to boost oral medicine manufacturing capacity in Europe for patients worldwide, Lilly has confirmed plans to invest ...

The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.

The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ...

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

Q3 2025 Earnings Call Transcript November 4, 2025 Martin Marietta Materials, Inc. misses on earnings expectations. Reported ...

Company cuts 9,000 jobs and lowers profit forecast as Wegovy sales slow. Q3 operating profit down 30% on competition ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar ...

Eli Lilly and rival drugmaker Novo Nordisk are the leading companies in the GLP-1 space, but others are emerging. Among them is Pfizer; in September that company announced it would acquire Metsera, a ...